Human Microbiome Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Product (Prebiotics, Probiotics, Medical Food, Supplements, Others), By Application (Therapeutic, Diagnostic), By Disease (Infectious Disease, Endocrine and Metabolic Disorders, Gastrointestinal Diseases, Cancer, Others), By Technology (Genomics, Proteomics, Metabolomics), By Type (FMT, Peptide, Live Biotherapeutic Product, Others), By Region & Competition, 2020-2030F
Market Overview
Global Human Microbiome market was valued at USD 615.25 Million in 2024 and is expected to reach USD 1524.05 Million by 2030 with a CAGR of 16.28%. The Global Human Microbiome Market is experiencing a significant transformation, fueled by growing scientific recognition of the microbiome's impact on human health and disease, along with increasing investments from pharmaceutical and biotechnology firms. This market encompasses the development of diagnostics, therapeutics, and healthcare solutions aimed at leveraging or modifying the human microbiota comprising trillions of microorganisms that inhabit the human body for improved medical outcomes.
Key Market Drivers
Increased Application in Cancer Treatment
Research has demonstrated that the human microbiome plays a crucial role in modulating immune responses, which directly impacts the efficacy of immunotherapies and chemotherapy. Certain gut microbiota strains have been found to enhance the effectiveness of immune checkpoint inhibitors, leading to improved patient outcomes. Biotech firms and pharmaceutical companies are investing in microbiome-derived drugs that can be used as adjunct therapies to traditional cancer treatments. These therapies aim to reduce treatment-related toxicity, improve drug absorption, and enhance immune system resilience.
The surge in clinical trials exploring microbiome-based interventions for cancer treatment is accelerating market growth. Studies are investigating how gut microbiota composition influences cancer progression and response to therapy. Rajiv Gandhi Cancer Institute and Research Centre (RGCIRC) has established itself as a premier clinical trial site, earning recognition from leading global cancer research institutions and pharmaceutical companies. With a track record of participation in over 300 national and international clinical trials, the center plays a pivotal role in advancing oncology research and innovative cancer therapies across diverse cancer types. Leading biotech firms and research institutions are forming strategic partnerships to develop microbiome-based cancer solutions. Increased funding from government agencies and private investors is driving innovation in microbiome therapeutics.
The integration of microbiome profiling into precision oncology is enabling personalized treatment plans tailored to individual patients. AI-driven microbiome analysis is helping identify biomarkers that predict cancer treatment responses. Regulatory bodies are recognizing the potential of microbiome-based therapies, leading to faster approvals and standardization efforts. The market is witnessing expansion into emerging economies, where cancer prevalence is rising.
Key Market Challenges
Scientific Complexity and Limited Understanding of Microbiome Functions
One of the most fundamental challenges impeding market growth is the incomplete and complex understanding of the human microbiome’s structure, function, and interactions with host physiology. Despite major research advancements, scientists still face difficulties in: Differentiating between beneficial, neutral, and harmful microbes, Understanding causal relationships between microbiome imbalances and specific diseases, Establishing universal biomarkers or reference ranges for “healthy” microbiota.
This scientific uncertainty limits the ability of researchers and companies to design effective, targeted, and reproducible microbiome-based therapies. Moreover, it complicates clinical trial design and makes it harder to validate efficacy, slowing product development and investor confidence.
Key Market Trends
Shift Toward Personalized Microbiome-Based Therapies
The most significant trends fueling market growth is the rapid evolution of personalized medicine powered by microbiome insights. As scientific understanding of the human microbiome deepens, it is becoming increasingly clear that microbial compositions vary significantly across individuals. This has led to a paradigm shift from generalized probiotic or therapeutic approaches toward personalized microbiome interventions, including: Tailored probiotics and synbiotics based on individual gut flora, Microbiome profiling and diagnostics to guide treatment decisions, Customized dietary recommendations to optimize gut health and disease prevention.
This trend aligns with the broader healthcare movement toward precision medicine, offering more effective, safer, and targeted interventions. As genomic sequencing and microbiome mapping technologies become more accessible and affordable, personalized microbiome-based therapies are poised to redefine patient care.
Key Market Players
Report Scope:
In this report, the Global Human Microbiome Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Human Microbiome Market.
Available Customizations:
Global Human Microbiome market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Global Human Microbiome market was valued at USD 615.25 Million in 2024 and is expected to reach USD 1524.05 Million by 2030 with a CAGR of 16.28%. The Global Human Microbiome Market is experiencing a significant transformation, fueled by growing scientific recognition of the microbiome's impact on human health and disease, along with increasing investments from pharmaceutical and biotechnology firms. This market encompasses the development of diagnostics, therapeutics, and healthcare solutions aimed at leveraging or modifying the human microbiota comprising trillions of microorganisms that inhabit the human body for improved medical outcomes.
Key Market Drivers
Increased Application in Cancer Treatment
Research has demonstrated that the human microbiome plays a crucial role in modulating immune responses, which directly impacts the efficacy of immunotherapies and chemotherapy. Certain gut microbiota strains have been found to enhance the effectiveness of immune checkpoint inhibitors, leading to improved patient outcomes. Biotech firms and pharmaceutical companies are investing in microbiome-derived drugs that can be used as adjunct therapies to traditional cancer treatments. These therapies aim to reduce treatment-related toxicity, improve drug absorption, and enhance immune system resilience.
The surge in clinical trials exploring microbiome-based interventions for cancer treatment is accelerating market growth. Studies are investigating how gut microbiota composition influences cancer progression and response to therapy. Rajiv Gandhi Cancer Institute and Research Centre (RGCIRC) has established itself as a premier clinical trial site, earning recognition from leading global cancer research institutions and pharmaceutical companies. With a track record of participation in over 300 national and international clinical trials, the center plays a pivotal role in advancing oncology research and innovative cancer therapies across diverse cancer types. Leading biotech firms and research institutions are forming strategic partnerships to develop microbiome-based cancer solutions. Increased funding from government agencies and private investors is driving innovation in microbiome therapeutics.
The integration of microbiome profiling into precision oncology is enabling personalized treatment plans tailored to individual patients. AI-driven microbiome analysis is helping identify biomarkers that predict cancer treatment responses. Regulatory bodies are recognizing the potential of microbiome-based therapies, leading to faster approvals and standardization efforts. The market is witnessing expansion into emerging economies, where cancer prevalence is rising.
Key Market Challenges
Scientific Complexity and Limited Understanding of Microbiome Functions
One of the most fundamental challenges impeding market growth is the incomplete and complex understanding of the human microbiome’s structure, function, and interactions with host physiology. Despite major research advancements, scientists still face difficulties in: Differentiating between beneficial, neutral, and harmful microbes, Understanding causal relationships between microbiome imbalances and specific diseases, Establishing universal biomarkers or reference ranges for “healthy” microbiota.
This scientific uncertainty limits the ability of researchers and companies to design effective, targeted, and reproducible microbiome-based therapies. Moreover, it complicates clinical trial design and makes it harder to validate efficacy, slowing product development and investor confidence.
Key Market Trends
Shift Toward Personalized Microbiome-Based Therapies
The most significant trends fueling market growth is the rapid evolution of personalized medicine powered by microbiome insights. As scientific understanding of the human microbiome deepens, it is becoming increasingly clear that microbial compositions vary significantly across individuals. This has led to a paradigm shift from generalized probiotic or therapeutic approaches toward personalized microbiome interventions, including: Tailored probiotics and synbiotics based on individual gut flora, Microbiome profiling and diagnostics to guide treatment decisions, Customized dietary recommendations to optimize gut health and disease prevention.
This trend aligns with the broader healthcare movement toward precision medicine, offering more effective, safer, and targeted interventions. As genomic sequencing and microbiome mapping technologies become more accessible and affordable, personalized microbiome-based therapies are poised to redefine patient care.
Key Market Players
- Enterome Bioscience SA
- Yakult Honsha Co. Ltd.
- 4 D Pharma
- Evelo Biosciences
- Seres Therapeutics Inc.
- Vedanta Biosciences
- Second Genome Inc.
- Quantibiome
- Rebiotix Inc.
- Microbiome Therapeutics LLC
Report Scope:
In this report, the Global Human Microbiome Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Human Microbiome Market, By Product:
- Prebiotics
- Probiotics
- Medical Food
- Supplements
- Others
- Human Microbiome Market, By Application:
- Therapeutic
- Diagnostic
- Human Microbiome Market, By Disease:
- Infectious Disease
- Endocrine and Metabolic Disorders
- Gastrointestinal Diseases
- Cancer
- Others
- Human Microbiome Market, By Technology:
- Genomics
- Proteomics
- Metabolomics
- Human Microbiome Market, By Type:
- FMT
- Peptide
- Live Biotherapeutic Product
- Others
- Human Microbiome Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Human Microbiome Market.
Available Customizations:
Global Human Microbiome market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. HUMAN MICROBIOME MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product (Prebiotics, Probiotics, Medical Food, Supplements, Others)
5.2.2. By Application (Therapeutic, Diagnostic)
5.2.3. By Disease (Infectious Disease, Endocrine and Metabolic Disorders, Gastrointestinal Diseases, Cancer, Others)
5.2.4. By Technology (Genomics, Proteomics, Metabolomics)
5.2.5. By Type (FMT, Peptide, Live Biotherapeutic Product, Others)
5.2.6. By Region
5.2.7. By Company (2024)
5.3. Market Map
6. NORTH AMERICA HUMAN MICROBIOME MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product
6.2.2. By Application
6.2.3. By Disease
6.2.4. By Technology
6.2.5. By Type
6.2.6. By Country
6.3. North America: Country Analysis
6.3.1. United States Human Microbiome Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product
6.3.1.2.2. By Application
6.3.1.2.3. By Disease
6.3.1.2.4. By Technology
6.3.1.2.5. By Type
6.3.2. Canada Human Microbiome Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product
6.3.2.2.2. By Application
6.3.2.2.3. By Disease
6.3.2.2.4. By Technology
6.3.2.2.5. By Type
6.3.3. Mexico Human Microbiome Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product
6.3.3.2.2. By Application
6.3.3.2.3. By Disease
6.3.3.2.4. By Technology
6.3.3.2.5. By Type
7. EUROPE HUMAN MICROBIOME MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product
7.2.2. By Application
7.2.3. By Disease
7.2.4. By Technology
7.2.5. By Type
7.2.6. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Human Microbiome Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product
7.3.1.2.2. By Application
7.3.1.2.3. By Disease
7.3.1.2.4. By Technology
7.3.1.2.5. By Type
7.3.2. United Kingdom Human Microbiome Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product
7.3.2.2.2. By Application
7.3.2.2.3. By Disease
7.3.2.2.4. By Technology
7.3.2.2.5. By Type
7.3.3. Italy Human Microbiome Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Product
7.3.3.2.2. By Application
7.3.3.2.3. By Disease
7.3.3.2.4. By Technology
7.3.3.2.5. By Type
7.3.4. France Human Microbiome Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Product
7.3.4.2.2. By Application
7.3.4.2.3. By Disease
7.3.4.2.4. By Technology
7.3.4.2.5. By Type
7.3.5. Spain Human Microbiome Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Product
7.3.5.2.2. By Application
7.3.5.2.3. By Disease
7.3.5.2.4. By Technology
7.3.5.2.5. By Type
8. ASIA-PACIFIC HUMAN MICROBIOME MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product
8.2.2. By Application
8.2.3. By Disease
8.2.4. By Technology
8.2.5. By Type
8.2.6. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Human Microbiome Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product
8.3.1.2.2. By Application
8.3.1.2.3. By Disease
8.3.1.2.4. By Technology
8.3.1.2.5. By Type
8.3.2. India Human Microbiome Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product
8.3.2.2.2. By Application
8.3.2.2.3. By Disease
8.3.2.2.4. By Technology
8.3.2.2.5. By Type
8.3.3. Japan Human Microbiome Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product
8.3.3.2.2. By Application
8.3.3.2.3. By Disease
8.3.3.2.4. By Technology
8.3.3.2.5. By Type
8.3.4. South Korea Human Microbiome Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product
8.3.4.2.2. By Application
8.3.4.2.3. By Disease
8.3.4.2.4. By Technology
8.3.4.2.5. By Type
8.3.5. Australia Human Microbiome Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product
8.3.5.2.2. By Application
8.3.5.2.3. By Disease
8.3.5.2.4. By Technology
8.3.5.2.5. By Type
9. SOUTH AMERICA HUMAN MICROBIOME MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product
9.2.2. By Application
9.2.3. By Disease
9.2.4. By Technology
9.2.5. By Type
9.2.6. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Human Microbiome Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product
9.3.1.2.2. By Application
9.3.1.2.3. By Disease
9.3.1.2.4. By Technology
9.3.1.2.5. By Type
9.3.2. Argentina Human Microbiome Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product
9.3.2.2.2. By Application
9.3.2.2.3. By Disease
9.3.2.2.4. By Technology
9.3.2.2.5. By Type
9.3.3. Colombia Human Microbiome Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product
9.3.3.2.2. By Application
9.3.3.2.3. By Disease
9.3.3.2.4. By Technology
9.3.3.2.5. By Type
10. MIDDLE EAST AND AFRICA HUMAN MICROBIOME MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product
10.2.2. By Application
10.2.3. By Disease
10.2.4. By Technology
10.2.5. By Type
10.2.6. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Human Microbiome Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Product
10.3.1.2.2. By Application
10.3.1.2.3. By Disease
10.3.1.2.4. By Technology
10.3.1.2.5. By Type
10.3.2. Saudi Arabia Human Microbiome Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Product
10.3.2.2.2. By Application
10.3.2.2.3. By Disease
10.3.2.2.4. By Technology
10.3.2.2.5. By Type
10.3.3. UAE Human Microbiome Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Product
10.3.3.2.2. By Application
10.3.3.2.3. By Disease
10.3.3.2.4. By Technology
10.3.3.2.5. By Type
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. GLOBAL HUMAN MICROBIOME MARKET: SWOT ANALYSIS
14. COMPETITIVE LANDSCAPE
14.1. Enterome Bioscience SA
14.1.1. Business Overview
14.1.2. Product & Service Offerings
14.1.3. Recent Developments
14.1.4. Financials (If Listed)
14.1.5. Key Personnel
14.1.6. SWOT Analysis
14.2. Yakult Honsha Co. Ltd.
14.3. 4 D Pharma
14.4. Evelo Biosciences
14.5. Seres Therapeutics Inc.
14.6. Vedanta Biosciences
14.7. Second Genome Inc.
14.8. Quantibiome
14.9. Rebiotix Inc.
14.10.Microbiome Therapeutics LLC
15. STRATEGIC RECOMMENDATIONS
16. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. HUMAN MICROBIOME MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product (Prebiotics, Probiotics, Medical Food, Supplements, Others)
5.2.2. By Application (Therapeutic, Diagnostic)
5.2.3. By Disease (Infectious Disease, Endocrine and Metabolic Disorders, Gastrointestinal Diseases, Cancer, Others)
5.2.4. By Technology (Genomics, Proteomics, Metabolomics)
5.2.5. By Type (FMT, Peptide, Live Biotherapeutic Product, Others)
5.2.6. By Region
5.2.7. By Company (2024)
5.3. Market Map
6. NORTH AMERICA HUMAN MICROBIOME MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product
6.2.2. By Application
6.2.3. By Disease
6.2.4. By Technology
6.2.5. By Type
6.2.6. By Country
6.3. North America: Country Analysis
6.3.1. United States Human Microbiome Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product
6.3.1.2.2. By Application
6.3.1.2.3. By Disease
6.3.1.2.4. By Technology
6.3.1.2.5. By Type
6.3.2. Canada Human Microbiome Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product
6.3.2.2.2. By Application
6.3.2.2.3. By Disease
6.3.2.2.4. By Technology
6.3.2.2.5. By Type
6.3.3. Mexico Human Microbiome Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product
6.3.3.2.2. By Application
6.3.3.2.3. By Disease
6.3.3.2.4. By Technology
6.3.3.2.5. By Type
7. EUROPE HUMAN MICROBIOME MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product
7.2.2. By Application
7.2.3. By Disease
7.2.4. By Technology
7.2.5. By Type
7.2.6. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Human Microbiome Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product
7.3.1.2.2. By Application
7.3.1.2.3. By Disease
7.3.1.2.4. By Technology
7.3.1.2.5. By Type
7.3.2. United Kingdom Human Microbiome Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product
7.3.2.2.2. By Application
7.3.2.2.3. By Disease
7.3.2.2.4. By Technology
7.3.2.2.5. By Type
7.3.3. Italy Human Microbiome Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Product
7.3.3.2.2. By Application
7.3.3.2.3. By Disease
7.3.3.2.4. By Technology
7.3.3.2.5. By Type
7.3.4. France Human Microbiome Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Product
7.3.4.2.2. By Application
7.3.4.2.3. By Disease
7.3.4.2.4. By Technology
7.3.4.2.5. By Type
7.3.5. Spain Human Microbiome Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Product
7.3.5.2.2. By Application
7.3.5.2.3. By Disease
7.3.5.2.4. By Technology
7.3.5.2.5. By Type
8. ASIA-PACIFIC HUMAN MICROBIOME MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product
8.2.2. By Application
8.2.3. By Disease
8.2.4. By Technology
8.2.5. By Type
8.2.6. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Human Microbiome Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product
8.3.1.2.2. By Application
8.3.1.2.3. By Disease
8.3.1.2.4. By Technology
8.3.1.2.5. By Type
8.3.2. India Human Microbiome Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product
8.3.2.2.2. By Application
8.3.2.2.3. By Disease
8.3.2.2.4. By Technology
8.3.2.2.5. By Type
8.3.3. Japan Human Microbiome Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product
8.3.3.2.2. By Application
8.3.3.2.3. By Disease
8.3.3.2.4. By Technology
8.3.3.2.5. By Type
8.3.4. South Korea Human Microbiome Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product
8.3.4.2.2. By Application
8.3.4.2.3. By Disease
8.3.4.2.4. By Technology
8.3.4.2.5. By Type
8.3.5. Australia Human Microbiome Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product
8.3.5.2.2. By Application
8.3.5.2.3. By Disease
8.3.5.2.4. By Technology
8.3.5.2.5. By Type
9. SOUTH AMERICA HUMAN MICROBIOME MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product
9.2.2. By Application
9.2.3. By Disease
9.2.4. By Technology
9.2.5. By Type
9.2.6. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Human Microbiome Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product
9.3.1.2.2. By Application
9.3.1.2.3. By Disease
9.3.1.2.4. By Technology
9.3.1.2.5. By Type
9.3.2. Argentina Human Microbiome Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product
9.3.2.2.2. By Application
9.3.2.2.3. By Disease
9.3.2.2.4. By Technology
9.3.2.2.5. By Type
9.3.3. Colombia Human Microbiome Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product
9.3.3.2.2. By Application
9.3.3.2.3. By Disease
9.3.3.2.4. By Technology
9.3.3.2.5. By Type
10. MIDDLE EAST AND AFRICA HUMAN MICROBIOME MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product
10.2.2. By Application
10.2.3. By Disease
10.2.4. By Technology
10.2.5. By Type
10.2.6. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Human Microbiome Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Product
10.3.1.2.2. By Application
10.3.1.2.3. By Disease
10.3.1.2.4. By Technology
10.3.1.2.5. By Type
10.3.2. Saudi Arabia Human Microbiome Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Product
10.3.2.2.2. By Application
10.3.2.2.3. By Disease
10.3.2.2.4. By Technology
10.3.2.2.5. By Type
10.3.3. UAE Human Microbiome Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Product
10.3.3.2.2. By Application
10.3.3.2.3. By Disease
10.3.3.2.4. By Technology
10.3.3.2.5. By Type
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. GLOBAL HUMAN MICROBIOME MARKET: SWOT ANALYSIS
14. COMPETITIVE LANDSCAPE
14.1. Enterome Bioscience SA
14.1.1. Business Overview
14.1.2. Product & Service Offerings
14.1.3. Recent Developments
14.1.4. Financials (If Listed)
14.1.5. Key Personnel
14.1.6. SWOT Analysis
14.2. Yakult Honsha Co. Ltd.
14.3. 4 D Pharma
14.4. Evelo Biosciences
14.5. Seres Therapeutics Inc.
14.6. Vedanta Biosciences
14.7. Second Genome Inc.
14.8. Quantibiome
14.9. Rebiotix Inc.
14.10.Microbiome Therapeutics LLC
15. STRATEGIC RECOMMENDATIONS
16. ABOUT US & DISCLAIMER
